Psychiatry

A recent study suggests ketamine can significantly improve symptoms of PTSD and OCD—but this is based on a review of an insufficient number of randomized controlled trials.

A study identified homelessness and minority status as factors that impact clozapine prescription patterns.

A study found a 3.5-fold increased schizophrenia risk in those with hallucinogen-related emergency department visits.

Maternal SSRI use was linked to a higher risk of constipation in infants, while untreated maternal depression was tied to colic. Margolis discussed these findings at NASPGHAN.

Emraclidine fails to significantly reduce schizophrenia symptoms in phase 2 EMPOWER trials, with no statistical difference from placebo on PANSS score.

Linaclotide trial shows effective constipation relief for pediatric patients with neurodevelopmental disorders, with high treatment adherence and safety profile.

Phase 3 data shows lumateperone 42 mg significantly delayed relapse in patients with schizophrenia vs placebo, with 63% reduced relapse risk and good tolerance.

Teva presents 2 findings at Psych Congress 2024: TEV’749’s effects on social function and quality of life in adults with schizophrenia and risperidone adherence patterns.

In a recent phase 2a trial, SPN-820, a novel intracellular moderator of mTORC1, decreased suicidal ideation by 80%.

This Month in Review captures top FDA news, phase 2b data, and early research in the psychiatry field.

EMERGENT-4 and EMERGENT-5, phase 3, 52-week trials, showed xanomeline trospium chloride significantly improved schizophrenia symptoms across 52 weeks.

Sexual trauma and genetic risk independently and together raise mental illness risk, a new study found.

Alto Neuroscience's ALTO-100 failed to beat placebo in a phase 2b trial for depression, leading to a 60% stock drop.

In the complete response letter, the FDA classified deficiencies in the Abbreviated New Drug Application for ketamine as MINOR.

A study found that adding depression to Life's Essential 8 provides minimal improvements in predicting cardiovascular and all-cause mortality risk.

A new meta-analysis found elevated triglyceride levels in patients with major depressive disorder, potentially explaining the link between depression and cardiovascular risks.

A new study identifies antipsychotics to avoid for patients with schizophrenia who have cognitive deficits, including haloperidol, fluphenazine, and clozapine.

Research from Spain suggests long-term opioid use to treat fibromyalgia pain significantly raises the risk of depression, anxiety and sleep disorders in patients.

Factors, including older age at onset and longer length of stay, may predict longevity for schizophrenia in psychiatric long-term care settings.

Second-generation long-acting injectables were particularly underutilized, and especially among older patients.

A short-term rise in air pollution levels between neighboring days was significantly linked to an increased risk of schizophrenia hospitalizations in China.

Findings suggest obstetric complications are associated with more severe psychopathological phenotypes in schizophrenia and related disorders.

A study of more than 130k with schizophrenia revealed significant variability in relapse and treatment failure rates across different antipsychotics.

Being female and having bipolar II disorder were independent risk factors for serious AEs in a new study.

Findings highlight high healthcare resource utilization and costs but low psychotherapy utilization, frequent relapse, and pharmacologic therapy discontinuation.

In part 1 of 5, panel moderator gives an overview of the Special Report focusing on the approval of Xanomeline and tropism chloride capsules for schizophrenia.

A recent study shows the FDA's black-box warnings on antidepressants have led to decreased usage among youth, with an increase in suicide attempts and deaths observed.

A study reveals that individuals with schizophrenia spectrum disorders experience high rates of comorbid mental health conditions and receive minimally adequate treatment.

A study links conversion therapy with worse mental health, such as PTSD and depression, showing a need for legislative action and support for LGBTQ+ individuals.

This Month in Review features the approval of trospium chloride capsules (Cobenfy) as well as other clinical trials in the psychiatry field.